Saccharomyces boulardii (SB), a subspecies of S. cerevisiae, is a non-pathogenic biotherapeutic probiotic agent that supports the establishment of friendly bacteria in the gastrointestinal tract (GIT). In the GIT, SB increases the production of secretory IgA (slgA), short-chain fatty acids and the activity of the brush border disaccharide digestive enzymes. It also discourages the growth of harmful micro-organisms and reduces digestive inflammatory mediators.